Ophthalmology Doctors in Rochester, PA Accepting Medicare
2 Ophthalmology doctors found. Showing 1 - 2
 Dr. George Raymond Zambelli Jr., M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 380 Adams St, Rochester, PA 15074 Phone: 724-728-5000 Fax: 724-728-3248 |
 Alison M Zambelli, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 380 Adams Street, Rochester, PA 15074 Phone: 724-728-5000 Fax: 724-728-3248 |
News Archive
Partisan strife, interest group concerns emerge in spending debate
The New York Times explores how intra-GOP allegiances to the business community are changing. Meanwhile, AARP acknowleges that adjustments must be made, but argues against cutting back entitlements. Also in the news, the director of the National Institutes of Health expresses his wariness about the impact sequestration could have on biomedical research.
Scientists discover mechanisms of GATA3 gene that govern blood stem cell self-renewal process
Stem cell scientists at the Princess Margaret Cancer Centre have discovered the gene GATA3 has a role in how blood stem cells renew themselves, a finding that advances the quest to expand these cells in the lab for clinical use in bone marrow transplantation, a procedure that saves thousands of lives every year.
CWRU/Cleveland Clinic consortium to focus on head, neck and spinal injuries
Cleveland Clinic and Case Western Reserve University are joining forces to form the Cleveland Traumatic Neuromechanics Consortium (TNC), which will investigate and develop better protection and treatment strategies for head, neck and spinal injuries related to sports, military service and automobile accidents.
Tarsa completes enrollment in Phase III ORACAL trial for postmenopausal osteoporosis
Tarsa Therapeutics, Inc. today announced progress in the ORACAL trial of its oral calcitonin product for the treatment of postmenopausal osteoporosis. The company has completed patient enrollment in this multinational, randomized, double-blind, placebo-controlled Phase III trial designed to enroll approximately 550 patients. In addition, Tarsa announced that the independent Data Monitoring Committee (DMC) for the ORACAL trial has completed two separate safety reviews of patient data and recommended that the trial proceed as planned.
Triple combination therapy with OM, AML, HCTZ more effective at lowering blood pressure
Results of a new study found that the investigational triple combination therapy of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) demonstrated significantly greater mean reductions at week 12 in blood pressure (37.1/21.8 mm Hg versus 27.5 to 30.0/15.1-18.0 mm Hg LS Mean Reductions, P< 0.0001), as compared to corresponding dual combination therapy (dual components).
› Verified 5 days ago